Lilly rides Mounjaro, Zepbound to better
Rapidly climbing sales of the new obesity drug Zepbound and its counterpart for diabetes, Mounjaro, pushed Eli Lilly to a better-than-expected first-quarter profit.
The drugmaker also hiked its sales and earnings forecast for 2024 beyond Wall Street’s expectations even as it hustles to boost manufacturing and catch up to surging demand for the drugs.
Lilly said it was still dealing with supply issues that also hampered the company in the fourth quarter. Company officials expect that to persist through this year, but they emphasized Tuesday that help was on the way.
They expect significant manufacturing increases to occur, starting in the back half of the year.
CEO David Ricks told analysts Tuesday that Lilly was undergoing “the most ambitious expansion plan in our company’s history.”
Indianapolis-based Eli Lilly and Co. recorded $517 million in sales from Zepbound, which received approval from U.S. regulators last November. Total Mounjaro sales more than tripled to $1.81 billion from $568 million in last year’s quarter.
Related articles
Massey, Perez hit homers to lead Royals in 8
KANSAS CITY, Mo. (AP) — Michael Massey and Salvador Perez homered as the Kansas City Royals beat the2024-05-22China Issues Action Plan to Advance Disability Prevention
Contact Us HomeNewsHighlightACWF NewsSocietyWom2024-05-22Top Chinese diplomat stresses China
NANNING, April 6 (Xinhua) -- Wang Yi, director of the Office of the Foreign Affairs Commission of th2024-05-22China to keep sharing development fruits with global businesses: vice president
BEIJING, March 26 (Xinhua) -- China will continue to promote the steady growth of its economy and sh2024-05-22Microsoft's AI chatbot will remember everything you do on a PC
REDMOND, Wash. (AP) — Microsoft wants laptop users to get so comfortable with its artificial intelli2024-05-22China to keep sharing development fruits with global businesses: vice president
BEIJING, March 26 (Xinhua) -- China will continue to promote the steady growth of its economy and sh2024-05-22
atest comment